

บรรณานุกรม

- กิตติพัฒน์ อุโฆษกิจ. (2549) พันธุศาสตร์. กรุงเทพมหานคร : สามลดา. คณะแพทยศาสตร์
จุฬาลงกรณ์มหาวิทยาลัย. (2546) เวชศาสตร์โมเลกุล. กรุงเทพมหานคร : Text and
Journal Publication.
- สุรินทร์ ปิยะโชคณากุล. (2548) พันธุวิศวกรรมเบื้องต้น. พิมพ์ครั้งที่ 3 กรุงเทพมหานคร :
สำนักพิมพ์มหาวิทยาลัยเกษตรศาสตร์.
- หัตยา กากีวงศ์. (2549) อณูพันธุศาสตร์. พิมพ์ครั้งที่ 2 เชียงใหม่ : บุญไชยการพิมพ์
- อุไรวรรณ วิจารณ์กุล. (2545) ดีเอ็นเอเทคโนโลยี. พิมพ์ครั้งที่ 2. พิษณุโลก : โรงพิมพ์ตระกูลไทย.
- Abbott, CA. et al. (1995) "Serum paraoxonase activity, concentration, and phenotype distribution
in diabetes mellitus and its relationship to serum lipids and lipoproteins" **Arterioscler
Thromb Vasc Biol.** 15(11) page 1812-1818.
- Adkins, S. et al. (1993) "Molecular basis for the polymorphic forms of human serum
paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or
B allozymes" **Am J Hum Genet.** 52(3) page 598-608.
- Agachan, B. et al. (2005) "Paraoxonase (PON1) 55 and 192 polymorphism and its effects to
oxidant-antioxidant system in Turkish patients with type 2 diabetes mellitus" **Physiol
Res.** 54 page 287-293.
- Aviram, M. et al. (1998) "Paraoxonase active site required for protection against LDL oxidation
involves its free sulfhydryl group and is different from that required for its
arylesterase/paraoxonase activity : selective action of human paraoxonase allozymes Q
and R" **Arterioscler Thromb Vasc Biol.** 18(10) page 1617-1624.
- Biggadike, K. et al. (2000) "Selective plasma hydrolysis of glucocorticoid gamma-lactones and
cyclic carbonates by the enzyme paraoxonase : an ideal plasma inactivation
mechanism" **J Med Chem.** 43(1) page 19-21.
- Billecke, S. et al. (2000) "Human serum paraoxonase (PON1) isozymes Q and R hydrolyze
lactones and cyclic carbonate esters" **Drug Metab Dispos.** 28(11) page 1335-1342.
- Boemi, M. et al. (2001) "Serum paraoxonase is reduced in type 1 diabetic patients compared to
non-diabetic, first degree relatives: influence on the ability of HDL to protect LDL
from oxidation" **Atherosclerosis.** 155(1) page 229-235.

- Brophy, VH. et al. (2001) "Effects of 5 Regulatory-Region Polymorphisms on Paraoxonase-Gene (*PON1*) Expression" **Am. J. Hum. Genet.** 68 page 1428-1436.
- Buckingham, L. and Flaws, ML. (2007) **Molecular Diagnostics Fundamentals, Methods & Clinical Applications.** Bangkok : iGroup Press Co., Ltd.
- Cole, TB. et al. (2003) "Expression of human paraoxonase (*PON1*) during development" **Pharmacogenetics.** 13(6) page 357-364.
- Datoine, TF. et al. (1998) "Decrease of serum paraoxonase activity in chronic renal failure" **J Am Soc Nephrol.** 9(11) page 2082-2088.
- Davies, HG. et al. (1996) "The effect of the human serum paraoxonase polymorphisms is reversed with diazoxon, soman and sarin" **Nat Genet.** 14(3) page 334-336.
- Deakin, SP. and James, RW. (2004) "Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1" **Clin Sci (Lond).** 107(5) page 435-447.
- Debord, J. et al. (1998) "Inhibition of arylesterase by aliphatic alcohols" **Chem Biol Interact.** 113(2) page 105-115.
- Draganov, DI. and La Du, BN. (2004) "Pharmacogenetics of paraoxonases: a brief review" **Naunyn Schmiedeberg's Arch Pharmacol.** 369 page 78-88.
- Ferre, N. et al. (2002) "Serum paraoxonase activity : a new additional test for the improved evaluation of chronic liver damage" **Clin Chem.** 48(2) page 261-268.
- Ferre, N. et al. (2003) "Regulation of serum paraoxonase activity by genetic, nutrition and lifestyle factors in the general population" **Clin Chem.** 49(9) page 1491-1497.
- Furlong, CE. et al. (1991) "Purification of rabbit and human serum paraoxonase. **Biochemistry.** 30(42) page 1013 -1040.
- Gardemann, A. et al. (2000) "The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease" **Atherosclerosis.** 152 page 421-431.
- Garin, MC. et al. (2005) "Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome" **J Clin Endocrinol Metab.** 90 page 2264-2269.
- Hangel, RA. (1999) "Paraoxonase genes and disease" **Ann Med.** 31 page 217-224.
- Hasselwander, O. et al. (1999) "Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients" **Kidney Int.** 56 page 289-298.

- Helbecquea, N. et al. (2004) "Paraoxonase 1 gene polymorphisms and dementia in humans" **Neurosci Lett.** 358 page 41-44.
- Holland, N. et al. (2006) "Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns" **Environ Health Perspect.** 114 page 985-991.
- Humbert, R. et al. (1993) "The molecular basis of the human serum paraoxonase activity polymorphism" **Nat Genet.** 3(1) page 73-76.
- Ikeda, Y. et al. (1998) "Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin dependent diabetes mellitus" **Metabolism.** 47(5) page 598-602.
- James RW, et al. (2000) "Promoter Polymorphism T(-107)C of the Paraoxonase *PON1* Gene Is a Risk Factor for Coronary Heart Disease in Type 2 Diabetic Patients" **Diabetes.** 49 : page 1390-1393.
- James, RW. Leviv, I. and Righetti, A. (2000) "Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease" **Circulation.** 101(19) page 2252-2257.
- James, RW. and Deakin, SP. (2004) "The importance of high-density lipoprotein for paraoxonase-1 secretion, stability and activity" **Free Radic Biol Med.** 37(12) page 1986-1994.
- Jarvik, G. et al. (2002) "Vitamin C and E intake are associated with increased paraoxonase activity" **Arterioscler Thromb Vasc Biol.** 22(8) page 1329-1333.
- Karban, A. et al. (2007) "Paraoxonase (PON)1 192R allele carriage is associated with reduced risk of inflammatory bowel disease" **Dig Dis Sci.** 52 page 2707-2715.
- La Du, BN. (1996) "Structural and functional diversity of paraoxonases" **Nat Med.** 2(11) page 1186-1187.
- La Du, BN. et al. (1999) "On the physiological role(s) of the paraoxonase" **Chem Bio Interact.** 119-120 page 379-388.
- Leviev, I. and James, RW. (2000) "Promoter polymorphisms of human *PON1* gene and serum paraoxonase activity and concentrations" **Arterioscler Thromb Vasc Biol.** 20(2) page 516-521.
- Li, HL. Liu, DP. and Liang, CC. (2003) "Paraoxonase gene polymorphisms, oxidative stress, and diseases. **J Mol Med.** 81 (12) page 766-779.

- Li, WF. et al. (2006) "Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes" **Environ Health Perspect.** 114 page 1233-1236.
- Li, WF. et al. (2009) "Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan" **Toxicol Appl Pharmacol.** 236 page 246-253.
- Leus, FR. et al. (2001) "PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients" **Atherosclerosis.** 154 page 641-649.
- Mackness, B. Durrington, P. and Connelly, P. (1998) "Human serum paraoxonase" **Gene pharmacol.** 31(3) page 329-336.
- Mackness, B. Durrington, P. and Mackness, M. (2002) "The paraoxonase gene family and coronary heart disease" **Curr Opin Lipidol.** 13(4) page 357-362.
- Mackness, B. et al. (2003) "Low paraoxonase activity predicts coronary events in the Caerphilly prospective study" **Circulation.** 107(22) page 2775-2779.
- Mackness, MI. et al. (1991) "Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus" **Atherosclerosis.** 86(2-3) page 193-199.
- Mackness, MI. et al. (1993) "Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase" **Atherosclerosis.** 104(1-2) page 129-135.
- Mackness, M, and Mackness, B. (2004) "Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?" **Free Radic Biol Med.** 37(9) page 1317-1323.
- Mana, BL. et al. (2010) "Genetic polymorphisms of Chinese patients with ischemic stroke and concurrent stenoses of extracranial and intracranial vessels" **J Clin Neurosci.** 17 page 1244-1247.
- Martinelli, N. et al. (2005) "Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease" **Clin Exp Med.** 5 page 20-30.
- Mazur, A. (1946) "An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates." **J Biol Chem.** 164 page 271-289.
- McKeown, EG. et al. (2004) "Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR" **Int J Epidemiol.** 33 page 971-978.

- Ng, C.J. et al. (2005) "The paraoxonase gene family and atherosclerosis" **Free Radic Biol Med.** 38(2) page 153-163.
- Nishio, E. and Watanabe, Y. (1997) "Cigarette smoke extracts inhibits plasma paraoxonase activity by modifications of the enzyme's free thiols" **Biochem Biophys Res Comm.** 236(2) page 289-293.
- Odawara, M. Tachi, Y. and Yamashita, K. (1997) "Paraoxonase polymorphism (Gln192Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus" **J Clin Endocrinol Metab.** 82(7) page 2257-2260.
- Oliveira, S.A. et al. (2004) "Annicchino-Bizzacchi, JM. PON1 M/L55 mutation protects high-risk patients against coronary artery disease" **Int J Cardiol.** 94 page 73-77.
- Osei-Hyiaman, D et al. (2001) "Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism?" **Eur J Endocrinol.** 144(6) page 639-644.
- Paragh, G. et al. (1998) "The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia" **Nephron.** 80(2) page 166-170.
- Paragh, G. et al. (2002) "Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia" **Eur Arch Psychiatry Clin Neurosci.** 252(2) page 63-67.
- Pasdar, A. et al. (2006) "Paraoxonase gene polymorphisms and haplotype analysis in a stroke population" **BMC Med Genet.** 7 page 28-34.
- Rajković, MG. et al. (2011) "Polymorphisms of pon1 and pon2 genes in hemodialyzed patients" **Clin Biochem.** 44 page 964-968.
- Ranade, K. et al. (2005) "Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke" **Stroke.** 36 page 2346-2350.
- Richter, R.J. and Furlong, C.E. (1999) "Determination of paraoxonase (PON1) status requires more than genotyping" **Pharmacogenetics.** 9(6) page 745-753.
- Rojas-Garcia, A.E. et al. (2005) "Genetic polymorphisms and activity of PON1 in a Mexican population" **Toxicol Appl Pharmacol.** 205 page 282-289.
- Saeed M, et al. (2007) "Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population" **Clin Genet.** 71 page 238-244.

- Sanghera, DK. et al. (1997) "Genetic polymorphism of paraoxonase and the risk of coronary heart disease" **Arterioscler Thromb Vasc Biol.** 17(6) page 1067-1073.
- Sarandol, E. et al. (2003) "Effects of red wine consumption on serum paraoxonase/arylesterase activities and on lipoprotein oxidizability in healthy man" **J Nutr Biochem.** 14(9) page 507-512.
- Senti, M. et al. (2003) "Antioxidant paraoxonase 1 activity in the metabolic syndrome" **J Clin Endocrinol Metab.** 88(11) page 5422-5426.
- Sepahvand, F. et al. (2007) "Paraoxonase phenotype distribution in a healthy Iranian population" **Basic Clin Pharmacol Toxicol.** 101 : page 104-107.
- Serrato, M. and Marian, AJ. (1995) "A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease" **J Clin Invest.** 96(6) page 3005-3008.
- Shin, B-S. (2009) "Paraoxonase gene polymorphism in south-western Korean population" **J Korean Med Sci.** 24 page 561-566.
- Slowik, A. et al. (2007) "Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population" **Cerebrovasc Dis.** 23 page 395-400.
- Sorenson, R. et al. (1999) "Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids apolipoprotein A-1 stabilize activity" **Arterioscler Thromb Vas Biol.** 19(9) page 2214-2225.
- Suehiro, T. et al. (2000) "A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression" **Atherosclerosis.** 150(2) page 295-298.
- Vandergaag, MS. et al. (1999) "Daily moderate alcohol consumption increases serum paraoxonase activity; a diet controlled, randomised intervention study in middle-aged men" **Atherosclerosis.** 147(2) page 405-410.
- Wang, X. et al. (2003) "Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population" **Arterioscler Thromb Vasc Biol.** 23 page 328-334.
- Watson, A. et al. (1995) "Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein" **J Clin Invest.** 96(6) page 2882-2891.

- Watzinger, N. et al. (2002) "Human paraoxonase1 gene polymorphisms and the risk of coronary heart disease: a community-based study" **Cardiology**. 98(3) page 116-122.
- Wheeler, J. et al. (2004) "Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies" **Lancet**. 363(9410) page 689-695.
- Yamada, Y. et al. (2003) "Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese" **J Hum Genet**. 48 page 469-475.
- Zama, T. et al. (1997) "A 192 Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese" **Arterioscler Thromb Vasc Biol**. 17(12) page 3565-3569.





ภาคผนวก

ประวัติย่อผู้วิจัย

คณะผู้วิจัย

หัวหน้าโครงการวิจัย

ชื่อ-นามสกุล อาจารย์ ดร. ชมพูนุท สินธุพิบูลย์กิจ
ประวัติการศึกษา ปร.ด. (เทคนิคการแพทย์) ม.มหิดล
วท.บ. (เทคนิคการแพทย์) ม.มหิดล
สถานที่ติดต่อ กลุ่มวิชาเคมีคลินิก คณะเทคนิคการแพทย์
มหาวิทยาลัยหัวเฉียวเฉลิมพระเกียรติ
โทรศัพท์ 0-2312-6300 ต่อ 1221

ผู้ร่วมวิจัย

ชื่อ-นามสกุล อาจารย์ทินกร เพิ่มพงศ์ไพบูลย์
ประวัติการศึกษา วท.ม. (เทคนิคการแพทย์) ม.มหิดล
วท.บ. (เทคนิคการแพทย์) ม.หัวเฉียวเฉลิมพระเกียรติ
สถานที่ติดต่อ กลุ่มวิชาเคมีคลินิก คณะเทคนิคการแพทย์
มหาวิทยาลัยหัวเฉียวเฉลิมพระเกียรติ
โทรศัพท์ 0-2312-6300 ต่อ 1221

ผู้ร่วมวิจัย

ชื่อ-นามสกุล ผู้ช่วยศาสตราจารย์ ดร. สุรรัตน์ พรธาดาวิทย์
ประวัติการศึกษา ปร.ด. (เทคนิคการแพทย์) ม.มหิดล
M.Sc. (Biotechnology) University of Texas at San Antonio,
U.S.A.
วท.บ. (เทคนิคการแพทย์) ม.เชียงใหม่
สถานที่ติดต่อ ภาควิชาเคมีคลินิก คณะเทคนิคการแพทย์ มหาวิทยาลัยมหิดล
โทรศัพท์ 0-2419-7168